Top analyst chimes in on bubbling debate about GlaxoSmithKline's future with a clear message: Let your £40B vaccines group go
Geoffrey Porges does not mince words.
The SVB Leerink analyst has a clear message for GlaxoSmithKline investors the day before Emma Walsmley and her top team are set to reveal their vision for the company after spinning out the consumer health unit. Writing approvingly of the rumored moves by activist investor Elliott Management, Porges argued in a new note that GSK should go further in its restructuring to unlock more value. First up: the vaccines group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.